The global hepatitis delta virus (HDV) infection market is experiencing growth driven by increasing awareness of HDV as a serious and complex liver disease, alongside advancements in research and the development of targeted therapies. HDV, a highly aggressive form of hepatitis that coexists with hepatitis B, remains a significant unmet medical need, as effective treatments for this viral infection are limited. Key players like Gilead Sciences, Inc. and Eiger BioPharmaceuticals are at the forefront, developing promising antiviral therapies, such as peginterferon lambda, which have shown encouraging results in clinical trials. The market is also supported by increasing healthcare investments in rare and complex diseases, as well as the growing global burden of chronic hepatitis infections, particularly in regions with high HBV prevalence. Despite challenges, including regulatory hurdles and high treatment costs, the market is set to expand as more effective and accessible treatment options for HDV become available, offering new hope for patients and contributing to improved outcomes in liver disease management.
Global Hepatitis Delta Virus (HDV) Infection Market is valued at USD 49.01 million in 2024 in 2022 and is expected to reach USD 71.54 million by 2032, with a growing CAGR of 4.84% during the forecast period 2025 to 2032.
To know more, visit https://www.databridgemarketresearch.com/reports/global-hepatitis-delta-virus-hdv-infection-market
Below are the Top Hepatitis Delta Virus (HDV) Infection Companies with a Significant Market Share:
|
Rank
|
Company
|
Overview
|
Product Portfolio
|
Sales Geographical Coverage
|
Developments
|
|
1.
|
Gilead Sciences, Inc.
|
Gilead Sciences, Inc. is a leading global biopharmaceutical company headquartered in Foster City, California. The company specializes in the discovery, development, and commercialization of innovative medicines in areas such as HIV, liver diseases, cancer, cardiovascular diseases, and inflammatory conditions. Gilead has a strong presence in the Global Hepatitis Delta Virus (HDV) Infection Market, with a significant focus on developing treatments for viral hepatitis, including HDV. Gilead’s portfolio includes pioneering therapies that have made significant advancements in the treatment of liver diseases, including chronic hepatitis B (HBV) and HDV. The company’s robust R&D pipeline aims to address unmet medical needs in the area of HDV, and its expertise in antiviral therapies positions it as a leader in this specialized market.
|
Hepcludex (Bulevirtide)
|
North America, Europe, Asia-Pacific, and Middle East and Africa
|
In September 2024, Gilead Sciences, Inc. and Genesis Therapeutics have formed a strategic collaboration to discover and develop novel therapies using advanced AI-driven drug discovery technologies. This partnership aims to accelerate the creation of innovative treatments, enhancing Gilead's pipeline and strengthening its position in the competitive biopharma industry.
|
|
2.
|
Eiger BioPharmaceuticals
|
Eiger BioPharmaceuticals is a biotechnology company focused on developing and commercializing therapies for rare and infectious diseases. Headquartered in Palo Alto, California, Eiger specializes in advancing treatments for chronic viral infections, including Hepatitis Delta Virus (HDV), a complex and challenging condition to treat. Eiger’s lead product, peginterferon lambda, is a promising treatment under investigation for HDV and has shown encouraging results in clinical trials. The company’s approach to addressing unmet needs in the HDV market involves leveraging innovative therapies that can improve the quality of life for patients with this severe and often neglected liver disease.
|
Zokinvy
|
North America
|
In December 2022, Lonafarnib, a novel prenylation inhibitor, was evaluated in the Phase 3 D-LIVR study for chronic HDV. It demonstrated significant virologic and biochemical improvements, with combination therapy showing a 19.2% response rate. Key benefits include increased histological improvement and ALT normalization, with manageable side effects.
|
Conclusion
Global hepatitis delta virus (HDV) infection market is on a positive growth trajectory, fueled by increasing awareness of the disease and promising advancements in treatment options. With key players like Gilead Sciences, Inc. and Eiger BioPharmaceuticals leading the way in developing innovative therapies, there is a growing optimism for better management and treatment of HDV. Although challenges such as regulatory obstacles and high treatment costs remain, the market is set to expand as more effective and accessible solutions become available. The continued investment in research and the increasing focus on rare liver diseases highlight the potential for improved patient outcomes, driving market growth and offering new opportunities in the treatment of HDV.
